Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00858832 · ClinicalTrials.gov registry record · NA
Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine
A NA study, sponsored by University of South Florida.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT00858832 is a NA study that has completed, run by University of South Florida. The registered enrollment target is 44 participants.
The verdict
NCT00858832, a NA study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
Endomyometritis is an "infection in the uterus". It can occur in up to 1 out of 5 women having unplanned cesarean deliveries. Antibiotics are routinely given at the time of Cesarean delivery, but the infection in the uterus can still occur. When endomyometritis occurs it can prolong the woman's stay in the hospital after birth, slow down her recovery time at home, and increase medical costs. Methergine is a medication that is routinely used to stop uterine hemorrhage (excessive bleeding from the uterus) that sometimes happens after delivery. Methergine works by contracting (tightening) the uterus. These contractions also help the uterus to expel or remove parts of the placenta that increase the chance of developing a uterine infection. This research study is being done to learn if routine use of Methergine can lower the chances of developing a uterine infection after cesarean delivery. Half of the women in this study will receive Methergine for a few days during their hospitalization after cesarean delivery. The other half of the women will not routinely receive Methergine.
Interventions
- DRUG Methergine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00858832
The ClinicalTrials.gov registry entry for NCT00858832 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Methergine is the first listed.
NCT00858832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00858832 about?
NCT00858832 is a clinical study titled "Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine". Endomyometritis is an "infection in the uterus". It can occur in up to 1 out of 5 women having unplanned cesarean deliveries. Antibiotics are routinely given at the time of Cesarean delivery, but the infection in the uterus can still occur. When endomyometritis occurs it can prolong the woman's stay...
What is the current status of trial NCT00858832?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2008-12. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00858832?
The interventions under investigation include: Methergine (DRUG).
Who is sponsoring clinical trial NCT00858832?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.